inixaciclib

Inixaciclib (NUV-422) is a selective, orally administered small molecule inhibitor of cyclin-dependent kinases 2, 4, and 6 (CDK2/4/6). By inhibiting these kinases, inixaciclib blocks phosphorylation of the retinoblastoma protein (Rb) early in the G1 phase of the cell cycle and prevents CDK-mediated transition from G1 to S phase. This mechanism disrupts tumor cell proliferation and is designed to overcome resistance mechanisms seen with existing CDK4/6 inhibitors by also targeting CDK2. Inixaciclib was developed by Nuvation Bio for oncology indications including high-grade gliomas (such as glioblastoma multiforme), breast cancer (including hormone receptor positive/HER2 negative subtypes), and metastatic castration-resistant prostate cancer. The drug demonstrated favorable blood-brain barrier penetration and was granted FDA Fast Track designation for high-grade gliomas. However, clinical development was discontinued following safety concerns related to uveitis and regulatory feedback[1][2][4][5][7].

Other names

inixaciclibNUV-422NUV422NUV 422